Testing an added blood-thinning drug after a stroke from narrowed large arteries
Tests cilostazol added to standard blood thinners in adults with stroke from artery narrowing.
Key facts
- Who runs it
- Asan Medical Center
- Where
- Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Jeju City, Jeonju, Seoul, and Yangsan, South KoreaSee the 24 sites
- Trial code
- Registry title
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 2,340 people, planned
- Started
- 10 Jul 2025
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Aspirin
- Clopidogrel
- Cilostazol
- Placebo
- Record updated
- 27 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have just had a stroke caused by hardening and narrowing of a large artery, and who can give consent within 72 hours of the stroke starting.
- Age
- 20 years or older
- Sex
- Women and men can join.
- Disease stage
- Acute stroke from large artery atherosclerosis (inside or outside the skull). A scan shows a brain lesion and a narrowed artery next to it, with more than 50% diameter reduction, confirmed by MR angiography or CT angiography.
Main reasons for not taking part
- Large stroke that prevents starting antiplatelet treatment
- Bleeding in the brain, or early bleeding in the stroke area
- Previous mRS higher than 2
- Needs blood-thinning (anticoagulant) treatment
- Cannot take aspirin, clopidogrel or cilostazol
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age of 20 years or older
- Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR angiography or CT angiography
- Informed consent obtained within 72h from stroke onset
- Acquisition of written informed consent prior to study entry
Who cannot take part
- Previous mRS higher than 2
- Pre-planned for surgery
- Combined with acute intracranial haemorrhage
- Large infarction unable to start antiplatelet treatment
- With initial haemorrhagic transformation
- Indicated for anticoagulation
- Contraindication for aspirin, clopidogrel or cilostazol
- Requirement of long term NSAID
- Unable to withdraw consent
- Unavailable to participate based on judgement of the investigator
- Participants of reproductive potential (PORP)/ Participants of childbearing potential (POCBP) who do not agree to practice methods of birth control or remain fully abstinent from sexual activity with the potential for conception
Where in South Korea
- Pusan National University HospitalBusan, South KoreaContact: Hanjun ChoTaking people
- Chungbuk National University HospitalCheongju-si, South KoreaContact: Hee-yoon Chae, MD, PhDTaking people
- Kyungpook National University Chilgok HospitalDaegu, South KoreaContact: Mi-Yeon Eun, MD, PhDTaking people
- Chungnam National University HospitalDaejeon, South KoreaContact: Jong Wook Shin, MD, PhDTaking people
- Eulji University HospitalDaejeon, South KoreaContact: Jae Guk Kim, MD, PhDTaking people
- Chonnam National University HospitalGwangju, South KoreaContact: Kang-Ho Choi, MD, PhDTaking people
- Hallym University Medical CenterGyeonggi-do, South KoreaContact: Minwoo Lee, MD, PhDTaking people
- Hanyang University Guri HospitalGyeonggi-do, South KoreaContact: Hyuk Sung Kwon, MD, PhDTaking people
- Korea University Ansan HospitalGyeonggi-do, South KoreaContact: Jin-Man Jung, MD, PhDTaking people
- Seoul National University Bundang HospitalGyeonggi-do, South KoreaContact: Beom Joon Kim, MD, PhDTaking people
- Gachon University Gil Medical CenterIncheon, South KoreaContact: SangHee Ha, MD, PhDTaking people
- Inha University HospitalIncheon, South KoreaContact: Cindy W Yoon, MD, PhDTaking people
- Jeju National University HospitalJeju City, South KoreaContact: Joong Goo Kim, MD, PhDTaking people
- jeonbuk National University HospitalJeonju, South KoreaContact: Hyun Goo Kang, MD, PhDTaking people
- Asan Medical CenterSeoul, South KoreaContact: Bum Joon Kim, MD, PhDTaking people
- Ewha Womans University Seoul HospitalSeoul, South KoreaContact: Tae-Jin Song, MD, PhDTaking people
- Hanyang University Seoul HospitalSeoul, South KoreaContact: Youngseo Kim, MD, PhDTaking people
- Korea University Guro HospitalSeoul, South KoreaContact: Chi Kyung Kim, MD, PhDTaking people
- Kyung Hee University HospitalSeoul, South KoreaContact: Hogeol Woo, MD, PhDTaking people
- Kyung Hee University Hospital at GangdongSeoul, South KoreaContact: Kyung Chul Noh, MD, PhDTaking people
- Samsung Medical CenterSeoul, South KoreaContact: Woo Keun Seo, MD, PhDTaking people
- The Catholic University of Korea, Seoul ST. Mary's HospitalSeoul, South KoreaContact: Minhwan Lee, MD, PhDTaking people
- Yonsei University Health System - Gangnam Severance HospitalSeoul, South KoreaContact: Yo Han Jung, MD, PhDNot yet recruiting
- Pusan National University Yangsan HospitalYangsan, South KoreaContact: Sungho Ahn, MD, PhDTaking people
About the trial
What the trial wants to find out
Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.
The 2 groups in the trial
- CA groupTreatment being tested
Aspirin 100mg qd (21days), clopidogrel 75mg qd (180days), Cilostazol SR 100mg x 2cap (180days). In case of stenting, aspirin will be added to cilostazol and clopidogrel until 90 days after stenting.
Treatment: Aspirin, Clopidogrel, and Cilostazol
- PA groupPlacebo, for comparison
Aspirin 100mg (21days), clopidogrel 75mg qd (180days), Placebo x 2cap (180days). In case of stenting, aspirin will be added to placebo and clopidogrel until 90 days after stenting.
Treatment: Aspirin, Clopidogrel, and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial
- Plain-language title
- Testing an added blood-thinning drug after a stroke from narrowed large arteriesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 March 2026